Is adoptive T-cell therapy for solid tumors coming of age

P. Pedrazzoli, P. Comoli, D. Montagna, T. Demirer, M. Bregni

Research output: Contribution to journalArticle

Abstract

Among the novel biological therapeutics that will increase our ability to cure human cancer in years to come, adoptive cellular therapy is one of the most promising approaches. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. The results obtained with tumor-infiltrating lymphocytes therapy for melanoma, and virus-specific CTLs for EBV-associated malignancies are encouraging in terms of both ability to obtain clinical benefit and limited toxicity profile. In both settings, objective responses were obtained in at least 50% of treated patients. However, improvements to the clinical protocols, in terms of better patient selection and timing of administration, as well as cell product quality and availability, are clearly necessary to further ameliorate outcome, and logistical solutions are warranted to extend T-cell therapy beyond academic centers. In particular, there is a need to simplify cell production, in order to decrease costs and ease preparation. Promising implementations are underway, including harnessing the therapeutic potential of T cells transduced with TCRs directed against shared tumor antigens, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.

Original languageEnglish
Pages (from-to)1013-1019
Number of pages7
JournalBone Marrow Transplantation
Volume47
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Cell- and Tissue-Based Therapy
T-Lymphocytes
Neoplasms
Tumor-Infiltrating Lymphocytes
Immune Evasion
Translational Medical Research
Neoplasm Antigens
Therapeutics
Clinical Protocols
Human Herpesvirus 4
Patient Selection
Melanoma
Clinical Trials
Viruses
Costs and Cost Analysis

Keywords

  • immunotherapy
  • solid tumors
  • T-cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Is adoptive T-cell therapy for solid tumors coming of age. / Pedrazzoli, P.; Comoli, P.; Montagna, D.; Demirer, T.; Bregni, M.

In: Bone Marrow Transplantation, Vol. 47, No. 8, 08.2012, p. 1013-1019.

Research output: Contribution to journalArticle

@article{c15afec50b034af68b4f34fed07788b2,
title = "Is adoptive T-cell therapy for solid tumors coming of age",
abstract = "Among the novel biological therapeutics that will increase our ability to cure human cancer in years to come, adoptive cellular therapy is one of the most promising approaches. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. The results obtained with tumor-infiltrating lymphocytes therapy for melanoma, and virus-specific CTLs for EBV-associated malignancies are encouraging in terms of both ability to obtain clinical benefit and limited toxicity profile. In both settings, objective responses were obtained in at least 50{\%} of treated patients. However, improvements to the clinical protocols, in terms of better patient selection and timing of administration, as well as cell product quality and availability, are clearly necessary to further ameliorate outcome, and logistical solutions are warranted to extend T-cell therapy beyond academic centers. In particular, there is a need to simplify cell production, in order to decrease costs and ease preparation. Promising implementations are underway, including harnessing the therapeutic potential of T cells transduced with TCRs directed against shared tumor antigens, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.",
keywords = "immunotherapy, solid tumors, T-cells",
author = "P. Pedrazzoli and P. Comoli and D. Montagna and T. Demirer and M. Bregni",
year = "2012",
month = "8",
doi = "10.1038/bmt.2011.155",
language = "English",
volume = "47",
pages = "1013--1019",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Is adoptive T-cell therapy for solid tumors coming of age

AU - Pedrazzoli, P.

AU - Comoli, P.

AU - Montagna, D.

AU - Demirer, T.

AU - Bregni, M.

PY - 2012/8

Y1 - 2012/8

N2 - Among the novel biological therapeutics that will increase our ability to cure human cancer in years to come, adoptive cellular therapy is one of the most promising approaches. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. The results obtained with tumor-infiltrating lymphocytes therapy for melanoma, and virus-specific CTLs for EBV-associated malignancies are encouraging in terms of both ability to obtain clinical benefit and limited toxicity profile. In both settings, objective responses were obtained in at least 50% of treated patients. However, improvements to the clinical protocols, in terms of better patient selection and timing of administration, as well as cell product quality and availability, are clearly necessary to further ameliorate outcome, and logistical solutions are warranted to extend T-cell therapy beyond academic centers. In particular, there is a need to simplify cell production, in order to decrease costs and ease preparation. Promising implementations are underway, including harnessing the therapeutic potential of T cells transduced with TCRs directed against shared tumor antigens, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.

AB - Among the novel biological therapeutics that will increase our ability to cure human cancer in years to come, adoptive cellular therapy is one of the most promising approaches. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. The results obtained with tumor-infiltrating lymphocytes therapy for melanoma, and virus-specific CTLs for EBV-associated malignancies are encouraging in terms of both ability to obtain clinical benefit and limited toxicity profile. In both settings, objective responses were obtained in at least 50% of treated patients. However, improvements to the clinical protocols, in terms of better patient selection and timing of administration, as well as cell product quality and availability, are clearly necessary to further ameliorate outcome, and logistical solutions are warranted to extend T-cell therapy beyond academic centers. In particular, there is a need to simplify cell production, in order to decrease costs and ease preparation. Promising implementations are underway, including harnessing the therapeutic potential of T cells transduced with TCRs directed against shared tumor antigens, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.

KW - immunotherapy

KW - solid tumors

KW - T-cells

UR - http://www.scopus.com/inward/record.url?scp=84864866991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864866991&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.155

DO - 10.1038/bmt.2011.155

M3 - Article

C2 - 21804611

AN - SCOPUS:84864866991

VL - 47

SP - 1013

EP - 1019

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -